Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Ready to Enroll patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
Shuttle Pharmaceuticals | 8-K: Certificate of Amendment to Amended and Restated Certificate of Incorporation of Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals | 8-K: Poll Results of 2024 Stockholders Meeting
Shuttle Pharmaceuticals | 8-K: Current report
Shuttle Pharmaceuticals | DEF 14A: Definitive information statements
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory
Shuttle Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Shuttle Pharmaceuticals | 8-K: First Quarter 2024 Financial Results
Shuttle Pharmaceuticals | 8-K: Current report
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Fourth Quarter 2023 Corporate Update
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmicals Receives Notice of Nasdaq's Failure to Satisfy Continued Listing Rules and CEO Anatoly Dritschilo to Attend Emerging Growth Conference on March 6, 2024
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
Shuttle Pharmaceuticals | 8-K: Asset Purchase Agreement
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
No Data